F

    Fortress Biotech Inc Pref Series A (FBIOP)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $18.74
    +0.13 (+0.70%)

    Market Cap: $77.81M

    Last updated: Aug 31, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    69%(11/16)
    Avg Surprise
    +8.99%
    Streak
    9 Q

    Upcoming Estimates

    Mar 31, 2026
    EPS Consensus$N/A
    Revenue Consensus
    $16M
    Range$16M - $16M
    1 analysts
    Jun 30, 2026
    EPS Consensus$N/A
    Revenue Consensus
    $18M
    Range$18M - $18M
    1 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Sep 26EST
    		-N/A---
    Jun 26EST
    		-N/A---
    Mar 26EST
    		-N/A---
    Sep 25
    		$0.11$0.00N/ABeat+143.1%
    Jun 25
    		$0.45$0.00N/ABeat+1129.7%
    Mar 25
    		$-0.48$0.00N/AMiss-340.0%
    Dec 24
    		$-0.37$0.00N/AMiss-458.1%
    Jun 21
    		$-0.26$0.00N/AMiss-34.5%
    Mar 21
    		$-0.04$0.00N/AMiss+77.0%
    Dec 20
    		$-0.11$0.00N/AMiss+59.6%
    Sep 20
    		$-0.07$0.00N/AMiss+69.9%
    Jun 20
    		$-0.19$-0.27+29.63%Beat+20.8%
    Mar 20
    		$-0.19$-0.23+17.39%Beat-1050.0%
    Dec 19
    		$-0.27$-0.31+12.90%Beat+53.4%
    Sep 19
    		$-0.22$-0.30+26.67%Beat+40.5%
    Jun 19
    		$-0.24$-0.46+47.83%Beat+52.0%
    Mar 19
    		$0.02N/A+103.45%Beat+104.1%
    Dec 18
    		$-0.58$-0.58+0.00%Beat-163.6%
    Sep 18
    		$-0.37$-0.55+32.73%Beat+44.8%
    Jun 18
    		$-0.50$-0.59+15.25%Beat-16.3%
    Mar 18
    		$-0.49$-0.43-13.95%Miss-63.3%
    Dec 17
    		$-0.22N/A+65.08%Beat+50.0%
    Sep 17
    		$-0.67$-0.42-59.52%Miss-109.4%
    Jun 17
    		$-0.43$-0.29-48.28%Miss-
    Mar 17
    		$-0.30$-0.36+16.67%Beat-
    Dec 16
    		$-0.44$-0.31-41.94%Miss-
    Sep 16
    		$-0.32$-0.20-60.00%Miss-

    Dividends

    Dividend Metrics

    Yield0.00%
    Annual/Share$0.00
    Payout Ratio0.00%
    Frequency12
    View FBIOP's full dividend history

    Key Metrics

    Valuation
    P/E Ratio-64.62EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin163.30%Operating Margin-53.50%
    ROE116.00%ROIC87.45%
    Financial Health
    Debt/Equity0.04xInterest Coverage17.26x
    Current Ratio3.96xQuick Ratio3.83x
    Trading Statistics
    Beta1.21Avg Volume12.07K
    52-Week High$21.4352-Week Low$6.27

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$18.40
    SMA 20$18.81
    SMA 50$19.09
    SMA 200$14.36
    EMA 10$18.56
    EMA 20$18.67
    EMA 50$18.64
    EMA 200$15.17

    MACD

    Line: -0.15Signal: -0.17Hist: 0.01

    ADX

    ADX: 14.7+DI: 20.1-DI: 18.3

    Aroon & PSAR

    Aroon Up36.0
    Aroon Down88.0
    PSAR$19.35

    Bollinger Bands

    Upper Band$19.96
    Lower Band$17.65
    %B Position1232%(Upper)
    Band Width0.47

    RSI (14-Day)

    Neutral
    50.0

    Momentum Oscillators

    Stoch %K37.5
    Stoch %D28.6
    Williams %R-53.2
    ROC (10d)3.4%
    Momentum0.61
    CCI (20d)-6.9
    MFI (14d)21.0

    Volatility Measures

    ATR (14d)$0.42(2.3%)
    StdDev (20d)0.58
    Hist Vol24.1%(Moderate)

    Volume Flow

    VWAP$18.70
    OBV1.0M
    AD Line1.3M
    CMF (20d)0.302

    Volume Metrics

    Avg Vol (20d)11.7K
    Vol Ratio0.3x(Low)
    VWMA (20d)$18.74

    Pivot Points

    R3$18.99
    R2$18.87
    R1$18.74
    Pivot Point$18.62
    S1$18.49
    S2$18.37
    S3$18.24

    Advanced Oscillators

    TSI-12.30
    Ultimate Osc61.5
    KST-33.77

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$18.72M$16.04M$16.08M$17.63M$16.41M$13.14M$15.12M$14.63M$14.90M$13.03M$19.95M$34.75M
    Cost of Revenue$7.11M$7.34M$5.44M$5.75M$4.94M$4.79M$5.80M$5.29M$6.54M$6.00M$6.01M$6.43M
    Gross Profit$11.61M$8.69M$10.64M$11.88M$11.47M$8.35M$9.31M$9.34M$8.36M$7.03M$13.93M$28.32M
    Operating Expenses$21.61M$16.43M$15.43M$18.69M$47.95M$30.67M$36.66M$31.44M$36.14M$43.59M$33.55M$42.08M
    R&D$805,000$540,000$367,000$208,000$8.13M$3.94M$9.94M$9.45M$12.67M$24.84M$14.08M$20.35M
    SG&A$20.81M$15.89M$14.73M$17.41M$38.76M$25.66M$26.86M$21.99M$20.82M$17.94M$22.61M$21.73M
    Operating Income$-10,005,000$-7,739,000$-4,789,000$-6,811,000$-36,473,000$-22,317,000$-27,345,000$-22,095,000$-27,788,000$-36,566,000$-19,614,000$-13,758,000
    Interest Income$0$570,000$637,000$736,000$622,000$490,000$526,000$589,000$734,000$833,000$707,000$547,000
    Interest Expense$1.48M$3.37M$1.71M$2.42M$2.07M$2.51M$2.59M$6.21M$2.12M$2.60M$2.06M$2.53M
    Income Before Tax$900,000$142.29M$-6,213,000$8.85M$-11,654,000$-24,691,000$-25,979,000$-26,625,000$-28,824,000$-39,023,000$-28,605,000$-10,583,000
    Income Tax Expense$298,000$5.13M$-816,000$26,000$0$0$336,000$69,000$-2,565,000$-1,719,000$379,000$141,000
    Net Income$-468,000$110.37M$-3,937,000$5.85M$15.49M$-10,584,000$-6,765,000$-12,867,000$-10,948,000$-15,417,000$-9,279,000$-5,045,000
    EBITDA$3.35M$147.36M$-3,347,000$12.43M$-8,424,000$-20,990,000$-21,780,000$-21,066,000$-26,142,000$-35,839,000$-25,381,000$-5,954,000
    EBIT$2.38M$145.66M$-4,504,000$11.27M$-9,580,000$-22,181,000$-23,385,000$-24,389,000$-27,333,000$-37,030,000$-27,090,000$-8,706,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about FBIOP

    News

    ETFs Investing in Fortress Biotech, Inc. Stocks

    This article lists ETFs that include Fortress Biotech, Inc. (FBIO) stocks, highlighting how these funds make investing in stocks more accessible and potentially lower risk. It provides a table with details on two such ETFs: iShares Microcap ETF (IWC) and EA Bridgeway Omni Small-Cap Value ETF (BSVO), including their market value, weight of FBIO, issuer, management style, expense ratio, AUM, price, change, relative volume, and 3-year NAV total return. The ETFs are sorted by market value and offer insights into funds holding FBIO.

    TradingView•8/18/26•
    Neutral

    Fortress Biotech (NASDAQ:FBIO) Lowered to Hold Rating by Wall Street Zen

    Wall Street Zen has downgraded Fortress Biotech (NASDAQ:FBIO) from a "strong-buy" to a "hold" rating. The stock currently holds an average "Hold" rating among analysts with a consensus price target of $17.00. Fortress Biotech recently reported stronger-than-expected quarterly earnings, with EPS of -$0.08 and revenue of $18.72 million, surpassing analyst estimates.

    MarketBeat•8/15/26•
    Neutral

    Fortress Biotech: Q2 Earnings Snapshot

    This article is a placeholder for Fortress Biotech's Q2 earnings snapshot. It currently contains no detailed financial information or an actual earnings report. The provided content is minimal and primarily consists of privacy protection disclaimers.

    WKYC•8/14/26•
    Neutral

    Fortress Biotech Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

    Fortress Biotech (Nasdaq: FBIO) announced its financial results for the second quarter of 2026, reporting a 14% increase in net revenue to $18.7 million compared to the same period in 2025. Key highlights include Crystalys Therapeutics securing $130 million in Series B financing for dotinurad, expansion of Emrosi® payer access to over 150 million commercial lives, and encouraging clinical progress for partnered programs like anselamimab. The company ended the quarter with a strengthened cash position of $196.6 million.

    GlobeNewswire•8/14/26•
    Neutral

    Fortress Biotech (NASDAQ: FBIO) gains $158.9M from voucher sale and boosts cash

    Fortress Biotech reported a consolidated net income of $137.8 million for the first half of 2026, primarily due to a $158.9 million gain from the sale of a Rare Pediatric Disease priority review voucher by its subsidiary Cyprium. This sale significantly boosted the company's cash and cash equivalents to $196.6 million, up from $79.4 million at the end of 2025. Despite this, core operations remained unprofitable, showing a $17.7 million loss from operations, and dividends on Series A preferred stock remain paused, affecting the company's Form S-3 shelf registration eligibility.

    Stock Titan•8/14/26•
    Bullish

    Frequently Asked Questions About FBIOP

    Does FBIOP pay dividends?
    Fortress Biotech Inc Pref Series A (FBIOP) has a dividend payment track record. See the FBIOP dividend history page for its current payment status, yield, and streaks.
    What is FBIOP's market cap?
    Fortress Biotech Inc Pref Series A (FBIOP) has a market capitalization of $77.81M with a current stock price of $18.74.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In